Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia
Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia
  • Phase

    Phase 4
  • Study Type

  • Status

    Completed No Results Posted
  • Study Participants

This study is designed to compare the efficacy and drug tolerability of two strategies for the treatment of schizophrenia. The two strategies consist of utilizing, on the one hand, a conventional antipsychotic like haloperidol or flupentixol and, on the other hand, a newer antipsychotic compound like olanzapine, quetiapine or aripiprazole in patients with schizophrenia.
There is agreement in the psychiatry community that the so-called atypical antipsychotics should be considered first choice in the treatment of schizophrenic disorders. However, the general superiority of these newer antipsychotic drugs over the older conventional drugs could not be clearly demonstrated in recent controlled clinical trials. The discrepancy between every day's clinical perception and the results of clinical trials raises the question whether the studies performed so far employed the adequate methodological approach to represent the daily practice situation which is characterized by a wide variety of duration and type of the schizophrenic disorder, concomitant diseases, and medications. Moreover, some studies might not have been focused adequately on patient-relevant outcome variables.

The present study project is designed to answer these open questions. The innovative character of the study design is

that different neuroleptic strategies will be compared rather than single antipsychotic drugs, using
an enhanced biometric design, that provides a choice of treatment with respect to the individual patient though the trial as such is randomised controlled and double blind;
that clinically relevant endpoints such as quality of life will be the primary variables, and
inclusion and exclusion criteria lead to a study population representing clinical every day practice as near as possible.

Another innovatory procedure is that serum levels of the study drugs will be recorded twice during the study. The authors hope that their design might yield transfer effects for other clinical trials facing similar problems.
Study Started
Feb 28
Primary Completion
Aug 31
Study Completion
Mar 31
Last Update
Jun 22

Drug Olanzapine

Olanzapine 10, 15, or 20 mg / day

Drug Flupentixol

Flupentixol 6, 9, or 12 mg / day

Drug Quetiapine

Quetiapine 400, 600, or 800 mg / day

Drug Aripiprazole

Aripiprazole 10, 15, or 20 mg / day

Drug Haloperidol

Haloperidol 3, 4.5, or 6 mg / day

atypical antipsychotics Experimental

Olanzapine, Quetiapine, or Aripiprazole

typical antipsychotics Active Comparator

Haloperidol or Flupentixol


Inclusion Criteria:

age 18-65 years
necessity to establish new or change antipsychotic treatment due to unsatisfying results or side effects
written informed consent

Exclusion Criteria (amongst others):

Known or suspected hypersensitivity to olanzapine, quetiapine, aripiprazole, flupentixol or haloperidol
Acute suicidal tendency
"Einwilligungsvorbehalt (BGB)" or "Unterbringung (PsychKG)"
Organic psychosis
Parkinson Disease
History of malignant neuroleptic syndrome
QTc interval ≥ 0.5s / history of congenital QTc prolongation
No Results Posted